Skinvisible, Inc. SKVI
0.16 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
0.156 Day range 0.1561
0.154 52-week range 0.544
- YTD
- -32.26%
- 1 year
- -68.82%
- Market cap
- 844.08K
- EPS (ttm)
- -0.20
- YTD return
- -32.26%
- 1-year return
- -68.82%
- Volume
- 705
- Avg volume
- 312
- Open
- 0.1561
- Previous close
- 0.1562
- Day's range
- 0.156 – 0.1561
- 52-week range
- 0.154 – 0.544
- Earnings date
- Aug 14, 2023
2Y -0.1938 (-55.37%)
Next earnings
Aug 14, 2023
Expected Aug 14, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 19, 2024 | Sep 1, 2024 | 0.00 | -0.06 | — | — |
| Aug 15, 2024 | Jun 1, 2024 | 0.00 | -0.07 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.06 | — | — |
| Apr 16, 2024 | Dec 1, 2023 | 0.00 | -0.07 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.06 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
News
Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection 
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies 
Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development 
Promising Data on Transdermal Obesity Formulations Announced by Skinvisible 
Skinvisible Expands Obesity Patent Application for Transdermal Delivery 
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome 
Stocks That Hit 52-Week Highs On Tuesday - Stocks That Hit 52-Week Lows On Thursday
Your note
Sign in to keep a note on SKVI — it syncs with the Stock Master app.